Rotasiil Rotavirus Vaccine Description
Rotasiil (bovine rotavirus pentavalent vaccine [BRV-PV]) is a live attenuated bovine–human (UK) reassortant thermostable rotavirus vaccine containing rotavirus serotypes G1, G2, G3, G4, and G9 (>5.6 log10 fluorescent focus units/serotype/dose) and is delivered in lyophilized form with 2.5 mL of citrate bicarbonate buffer added for reconstitution before oral administration.
Rotasiil Rotavirus Vaccine Indication
Rotasiil is indicated for active immunization of healthy infants from the age of 6 weeks for the prevention of gastroenteritis due to rotavirus infection when administered as a 3-dose series
Rotasiil Rotavirus Vaccine News
July 2, 2021 - Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial
September 27, 2018 - Achieving WHO prequalification means that ROTASIIL will now be available for procurement by United Nations agencies and Gavi, the Vaccine Alliance, for use in low- and middle-income countries.
Rotasiil Rotavirus Vaccine Clinical Trial
Rotasiil has been tested in several clinical trials.